This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MMG Partners With Remedy Health Media To Bolster Clinical Trial Enrollment

Stocks in this article: OMC

ROCKVILLE, Md., Oct. 16, 2012 /PRNewswire/ -- MMG ( www.mmgct.com), a global health communications company specializing in clinical trial patient recruitment and retention, has formed an exclusive partnership with Remedy Health Media ( www.remedyhealthmedia.com) to deliver unique access to a larger pool of qualified potential clinical trial participants. Remedy Health Media (Remedy) is America's fastest growing health information and technology company, which produces a variety of clinical and wellness resources including Remedy's Healthy Living and Diabetes Focus and maintains publishing partnerships with globally recognized institutions such as Johns Hopkins Medicine and the University of California, Berkeley School of Public Health.

This partnership offers significant value to MMG's clients by effectively reaching their desired audiences through Remedy's community of more than 150 million health-information-seeking patients and caregivers. Remedy's 28.4 million unique monthly visitors (comScore, September 2012) proactively seek treatment options for therapeutic areas that match MMG's category coverage.

Additional benefits for MMG's clients include:

  • Guaranteed increase in already-high number of patient referrals;
  • Strengthened patient retention rate through Remedy's HIPAA-compliant, proprietary mobile content and adherence tools; and
  • Exclusive media placement capabilities.

"We were drawn to this partnership with Remedy because we want to be able to provide information to patients faster while offering our clients even higher value for their investment," said John Benbrook, CEO of MMG. "We look forward to leveraging MMG's unique presence within Remedy's expansive network of trusted health resources to deliver even greater measurable results."  

Michael Cunnion, CEO of Remedy Health Media, said, "We're thrilled to partner with MMG because this is a perfect opportunity to provide better information, tools and connectivity to patients who are actively seeking clarity in the trial enrollment process."

About Remedy Health MediaRemedy Health Media is a privately held health information and technology company with tools that help millions of patients and caregivers live healthier, more fulfilled lives. Remedy Health Media aims to empower lives with the information and applications needed to efficiently navigate the healthcare landscape, and as a result, to permit better health outcomes through use of our products and services.

About MMG MMG is the premier global health communications organization specializing in patient recruitment and retention. With experience in more than 70 countries and across a vast range of therapeutic areas, populations, and study types, MMG provides strategies specially crafted for study teams and patient populations while delivering the best return on investment for the sponsor. MMG, a Ketchum company, is a part of Diversified Agency Services, a division of Omnicom Group Inc.

About Diversified Agency ServicesDiversified Agency Services (DAS), a division of Omnicom Group Inc. (NYSE: OMC) ( www.omnicomgroup.com), manages Omnicom's holdings in a variety of marketing communications disciplines. DAS includes over 200 companies, which operate through a combination of networks and regional organizations, serving international and local clients through more than 700 offices in 71 countries.

About Omnicom Group Inc.Omnicom Group Inc. ( www.omnicomgroup.com) is a leading global marketing and corporate communications company. Omnicom's branded networks and numerous specialty firms provide advertising, strategic media planning and buying, digital and interactive marketing, direct and promotional marketing, public relations, and other specialty communications services to over 5,000 clients in more than 100 countries.

SOURCE MMG

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs